Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access
August 23, 2024
August 23, 2024
CHICAGO, Illinois, Aug. 23 -- The Alzheimer's Association issued the following news release on Aug. 22, 2024:
The Alzheimer's Association welcomes today's decision by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi(R) (lecanemab) for the treatment of Alzheimer's disease. However, while celebrating this milestone -- the first Alzheimer's disease modifying treatment approved in the U.K. -- the decision by the National Institute for He . . .
The Alzheimer's Association welcomes today's decision by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi(R) (lecanemab) for the treatment of Alzheimer's disease. However, while celebrating this milestone -- the first Alzheimer's disease modifying treatment approved in the U.K. -- the decision by the National Institute for He . . .